We’ve got a flat open on our hands this morning but there’s plenty of action (again) in the bio-wreck sector — the bulk of today’s ‘gapping up’ list are biotechs.
On Today’s Calendar:
- no reports but we’ve got some Fed speak at 9:30 and 1:20
More Calendars: U.S. Earnings | Conf. Calls | Surprises | IPO | Economic
Potential swing trades:
See one of the recent ‘Chart Reading‘ posts for some potential swing candidates.
Potential day trades:
(From Briefing.com)
Gapping Down
Gapping down on weak earnings/guidance: HPOL -12.4%, CACH -8.6%, VAL -6.4%, STX -5.6% (also downgraded to Buy at Needham… down in sympathy WDC -1.9%), MOS -5.5% (also downgraded to Mkt Perform at BMO), LWSN -2.0%… Other news: ADLR -54.4% (announces development program for OBD on hold while findings from safety study are evaluated; also multiple downgrades), GSX -16.3% (announces a 10 mln share common stock offering), NKTR -3.8% (NY Times reports that PFE/NKTR’s “Exubera, the inhaled-insulin for Diabetes is lagging”), IMAX -3.0% (receives Nasdaq staff determination letter), AGEN -2.6% (profit-taking after yesterday’s 43% surge).
Gapping Up
Gapping up on strong earnings/guidance: DIVX +15.7%, CHRD +9.4%, MYL +4.7%… Small-cap Biotechs up on follow-through momentum, news, & ahead of today’s BIO-Windhover Conference presentations: MEMY +33.5%, RNVS +24.7% (co and Pfizer extend research collaboration), PCOP +17.9% (PS433540 shown to be well tolerated and potentially suited for once daily administration), NUVO +10.1% (continued momentum from yesterday; also BofA says DNDN progenge news may have helped NUVO – Bloomberg), TGEN +11.6%, INCY +9.1% (positive comments from Cramer), GTOP +7.5%, GLGC +7.1%, PCYC +6.5%, LJPC +6.4%, DNDN +5.6% (shorts continue to get squeezed), TELK +5.4% (announces Telcyta presentations at AACR meeting), PGNX 5.0 (seen as beneficiary of failure of GSK’s Entereg safety trial), LJPC 4.9 (initiated with a Buy and $11 tgt at A.G Edwards)… Other news: TLCV +11.3% (to repurchase up to 20 mln common shares in tender offer), LUNA +9.3% (receives $1.6 mln contract), ROSE +7.6% (positive comments from Cramer).
Disclaimer & How I use this list
